Principal Street Partners LLC acquired a new stake in Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 49,467 shares of the company's stock, valued at approximately $472,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Sierra Ocean LLC purchased a new position in Haleon during the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. purchased a new position in Haleon during the fourth quarter valued at approximately $35,000. FIL Ltd raised its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after buying an additional 1,270 shares in the last quarter. Spire Wealth Management bought a new position in Haleon in the fourth quarter worth approximately $39,000. Finally, Addison Advisors LLC lifted its holdings in Haleon by 28.7% during the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after buying an additional 1,106 shares during the period. 6.67% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several research firms recently commented on HLN. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a research note on Thursday. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a report on Friday, May 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Six analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.25.
Check Out Our Latest Report on HLN
Haleon Stock Performance
Shares of HLN stock traded up $0.10 on Friday, hitting $11.16. The company had a trading volume of 20,774,144 shares, compared to its average volume of 8,245,055. Haleon plc has a twelve month low of $8.25 and a twelve month high of $11.19. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $50.30 billion, a P/E ratio of 32.82, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The company has a 50-day moving average price of $10.30 and a 200-day moving average price of $9.91.
Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities research analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.
Haleon Increases Dividend
The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This is a boost from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio (DPR) is 58.97%.
About Haleon
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Articles
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
